secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001171843-22-007002
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q3 net loss $18.6M, cash $142.3M; HBV and NASH programs advancing
------------------------------------------------------------------------

- Net loss $18.6M ($0.44 per share) vs $33.1M ($0.78) a year ago; R&D spending fell to $17.8M.
- Cash, equivalents, and investments $142.3M as of Sep 30, 2022, down from $205.8M at Dec 31, 2021.
- HBV CAM ALG-000184 initiated up-to-48-week dosing; siRNA ALG-125755 SAD in healthy volunteers ongoing.
- NASH THR-beta agonist ALG-055009 MAD data to be presented at AASLD; plans to advance to Phase 2.
- Pan-coronavirus protease inhibitor ALG-097558 entering Phase 1 enabling studies; clinical eval expected Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/0001171843-22-007002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/f8k_110222.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer